Docstoc

Esophageal Cancer Therapeutics - Pipeline Assessment and Market Forecast to 2017

Document Sample
Esophageal Cancer Therapeutics - Pipeline Assessment and Market Forecast to 2017 Powered By Docstoc
					Esophageal Cancer Therapeutics - Pipeline Assessment and Market Forecast to 2017

Esophageal Cancer Therapeutics Market is forecast to Show High Growth Until 2017

GlobalData estimates that the global esophageal cancer therapeutics market was valued at $243.8m in
2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 14% over the next seven
years, to reach $594.7m by 2017. This fast growth is primarily attributed to the strong pipeline and
onset of four promising molecules from 2014 onwards. The HER-2 expressing patients have access to
Herceptin (transtuzumab) which is approved for HER2-overexpressing metastatic gastroesophageal (GE)
junction adenocarcinoma along with some widely used off-label drugs such as cisplatin and capecitabine
and ECF (epirubicin,cisplatin and 5-FU) which have gone off-patent.

GlobalData analysis shows that the esophageal cancer therapeutics pipeline is strong, with 35 molecules
in various phases of clinical development, including 31 first-in-class molecules. The four promising first-
inclass products such as Avastin (bevacizumab), Erbitux (cetuximab), ramucirumab and Tykerb (lapitinib)
in late stage pipeline are expected to hit the market around 2014. These products possess mechanisms
of action different from currently used drugs. Thus the pipeline for the esophageal cancer therapeutics
market is strong.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Esophageal-Cancer-
Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017

The esophageal cancer therapeutics market is represented by Herceptin and some off-label drugs.
Cisplatin, Xeloda (capecitabine) and ECF are mainly used drugs for treating esophageal cancer.
Paclitaxel and carboplatin, 5-FU and leucovorin are also used but they have low response rates.
Herceptin from Genetech/Roche is prescribed as the first line and second line form of drug therapy for
the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma patients.
There are no other drugs which have been approved for non HER-2 overexpressing patients of
esophageal cancer. Any drug that could successfully cater to this untreated patient segment is expected
to reap revenues from the esophageal cancer therapeutics market.

GlobalData, the industry analysis specialist, has released its new report, “Esophageal Cancer
Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source
of information and analysis on the global Esophageal Cancer Therapeutics market. The report identifies
the key trends shaping and driving the global Esophageal Cancer Therapeutics market. The report also
provides insights on the prevalent competitive landscape and the emerging players expected to
significantly alter the market positioning of the current market leaders. Most importantly, the report
provides valuable insights on the pipeline products within the global Esophageal Cancer Therapeutics
sector. This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Esophageal-Cancer-Therapeutics-Pipeline-
Assessment-and-Market-Forecasts-to-2017

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America: +1 646 395 5477
Europe:                +44 207 753 4299
                       +44 1204 543 533
Asia Pacific:          +91 40 6616 6782

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:28
posted:6/24/2011
language:English
pages:2
Description: Esophageal Cancer Therapeutics Market is forecast to Show High Growth Until 2017